A case of blastic NK-cell lymphoma.
Akasaka
Emiko
E
Course of Specialized Clinical Science (Dermatology), Tokai University School of Medicine, Kanagawa, Japan. emiko-a@is.icc.u-tokai.ac.jp
Mabuchi
Tomotaka
T
Umezawa
Yoshinori
Y
Iwashita
Kenichi
K
Ohta
Yukinori
Y
Matsuyama
Takashi
T
Ozawa
Akira
A
D015703:Antigens, CD; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016130:Immunophenotyping; D017403:In Situ Hybridization; D007694:Killer Cells, Natural; D008198:Lymph Nodes / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D014750:Vincristine / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide